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Abstract
Objective: Identification of unanswered research questions about the management of gestational diabetes
mellitus (GDM) is necessary to focus future research endeavors. We developed a process for elucidating the
highest priority research questions on GDM.
Methods: Using a systematic review on GDM as a starting point, we developed an eight-step process:
(1) identification of research gaps, (2) feedback from the review’s authors, (3) translation of gaps into re-
searchable questions using population, intervention, comparators, outcomes, setting (PICOS) framework, (4) local
institutions’ stakeholders’ refinement of research questions, (5) national stakeholders’ use of Delphi method to
develop consensus on the importance of research questions, (6) prioritization of outcomes, (7) conceptual
framework, and (8) evaluation.
Results: We identified 15 high priority research questions for GDM. The research questions focused on medi-
cation management of GDM (e.g., various oral agents vs. insulin), delivery management for women with GDM
(e.g., induction vs. expectant management), and identification of risk factors for, prevention of, and screening for
type 2 diabetes in women with prior GDM. Stakeholders rated the development of chronic diseases in offspring,
cesarean delivery, and birth trauma as high priority outcomes to measure in future studies.
Conclusions: We developed an eight-step process using a multidisciplinary group of stakeholders to identify 15
research questions of high clinical importance. Researchers, policymakers, and funders can use this list to direct
research efforts and resources to the highest priority areas to improve care for women with GDM.
Introduction
Gestational diabetes mellitus (GDM) is a commonpregnancy complication, affecting about 7% of preg-
nancies in the United States, and its prevalence has been
increasing.1,2 GDM is associated with both perinatal and
longer-term maternal and offspring risks, such as cesarean
delivery,3,4 fetal macrosomia,3,5 development of type 2 dia-
betes in the mother,6 and obesity in the offspring.7 Because of
these risks and the potential implications of treatment,8,9
GDM is an important, emerging area for clinical, epidemio-
logic, and basic research. Notably, between 2001 and 2010,
MEDLINE included > 3000 citations indexed as ‘‘gestational
diabetes mellitus’’ compared with < 1700 citations in the prior
decade. In addition, the majority of clinical trials on GDM
have been published in the last 10 years.
In 2008, we completed an Agency for Healthcare Research
and Quality (AHRQ)-funded systematic review on specific
aspects of management of GDM.10 The review addressed 4
questions proposed by the American College of Obstetricians
and Gynecologists (ACOG) because of their high clinical rel-
evance: (I) What are the risks and benefits of an oral diabetes
agent (e.g., glyburide), as compared with all types of insulin,
for GDM? (II) What is the evidence that elective labor in-
duction, cesarean delivery, or timing of induction is associ-
ated with benefits or harm to the mother and neonate? (III)
What risk factors are associated with the development of type
2 diabetes after a pregnancy with GDM? (IV) What are the
performance characteristics of diagnostic tests for type 2 di-
abetes in women with prior GDM?10 We identified 11,400
unique citations, independently reviewed titles, abstracts,
and full articles and included 45 articles, which included
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9 randomized controlled trials (RCT) that applied to review
questions I and II.10 We graded the evidence as either insuf-
ficient or low strength for addressing the 4 review questions,
suggesting widespread deficiencies in the field and the need
for higher-quality studies to address the gaps.10 Although the
review synthesized and graded the existing evidence, the next
step of identifying and prioritizing research gaps was de-
scriptive and not systematic, as few frameworks currently
exist to inform this final process.11 AHRQ recognized that
relying on systematic reviews to identify and report research
needs was not sufficient and, thus, has funded various pilot
studies, including the one reported here, to develop standard
methods.
The primary objective of this study was to identify clini-
cally important research questions for the management GDM
using a process that involved stakeholder input and the 2008
systematic review’s findings as a starting point. The second-
ary objectives were to prioritize outcomes to measure in
future trials and to highlight feasibility and study design
challenges related to the identified research questions.
Ultimately, the goal was to guide future research endeavors
on GDM management.
Materials and Methods
We developed and completed an eight-step process to
identify research needs for GDM. We describe the process that
began with the 2008 systematic review’s 4 original questions,
followed by the identification of research gaps and 17 research
questions, and ending with 15 final questions, which multi-
disciplinary stakeholders deemed to have the highest clinical
impact and potential benefit. We also described the methods
in more detail in the final report prepared for AHRQ12 and in
an article focused on the methods.13
Steps 1, 2, and 3: Identification of research gaps
from review and formulation of 17 research questions
In step 1, two investigators independently abstracted
statements about research gaps from the published AHRQ
evidence report10 and five articles based on findings from the
review.14–18 The two investigators compared and combined
the lists using a consensus process. In step 2, we sought
feedback from the eight authors of the 2008 systematic review
via electronic communication. The authors provided free-text
feedback about existing gaps identified within the review and
suggested additional deficiencies, including challenges in the
design of future studies. Readers are referred to the final re-
port for a tabulation of all identified gaps.12 For step 3, our
research team organized the list of gaps into the population,
intervention, comparators, outcomes, setting (PICOS) frame-
work. We then translated these gaps into 17 new research
questions.
Step 4: Refinement of the 17 research questions
by institutionally based local stakeholders
For step 4, we invited six stakeholders from our own in-
stitution (local stakeholders) with expertise in GDM research
or patient care to provide feedback on the 17 research ques-
tions. A list of the local stakeholders is available in the final
AHRQ report.12 This multidisciplinary group included two
academic obstetricians, one dietitian whose clinical practice is
focused on GDM, one epidemiologist whose research has
focused on diabetes, and two members with insight into the
patient perspective (a social worker and the director of a
Medicaid case management program for women with com-
plicated pregnancies), but no patients. Stakeholders first
completed an online questionnaire in which we listed the 17
draft research questions and asked them to comment on (1)
the clarity of the questions (or suggest alternate wording), (2)
the clinical benefit and importance of addressing the ques-
tions, using a 9-point Likert scale, where 9 indicated highly
clinically important/high clinical benefit and 1 indicated un-
likely to have clinical importance or benefit, and (3) the fea-
sibility for researchers to conduct a study that would address
the research questions, using a 9-point scale, where 9 indi-
cated highly feasible and 1 indicated unlikely to be feasible.
We refined these 17 research questions based on the online
feedback. The online questionnaire was developed using
SurveyGizmo (Widgix LLC, Boulder, CO).
We invited the six local stakeholders to an interactive in-
person meeting to solicit further feedback about missed re-
search gaps and develop informal consensus on the wording,
content of the research questions, and missed gaps. Finally,
we asked the local stakeholders to consider study design
needs and challenges for each of the research questions. Fol-
lowing step 4, we refined each question and added questions
suggested by the stakeholders to yield 19 research questions.
Step 5: Consensus development by national
stakeholders about research questions’
clinical benefit/importance, leading
to 15 final questions
We identified national leaders and experts in GDM and
invited nine of them to be stakeholders for this project (na-
tional stakeholders). They represented the areas of obstetrics
and gynecology, nutrition, epidemiology, research funders,
and consumers. A list of the national stakeholders is available
in the final AHRQ report.12 We used the Delphi method for
consensus development using an online form. The Delphi
method involves iterative rounds of responses by group
members, providing aggregated feedback about other mem-
bers’ responses until consensus is reached.19 A priori we de-
termined the maximum number of rounds to be three,
because we believed, based on prior experience with the
Delphi method, that consensus would be reached by then and
to minimize stakeholder burden. For each round, we used an
online instrument (SurveyGizmo) to gain feedback on the list
of the research questions. As with the local stakeholders, we
asked the national stakeholders to comment on the clarity of
each question (or to suggest alternate wording) and the clin-
ical benefit and importance of addressing each question, using
the same 9-point Likert scale. We categorized clinical benefit/
importance scores into high (between 7 and 9), medium (be-
tween 4 and 6), and low (between 1 and 3) clinical benefit/
importance. We defined achievement of consensus for each
research question as ‡ 75% (i.e., 7 of 9) of external stake-
holders’ ratings within the same single category. We refined
all research questions based on comments. The research
questions without consensus were retained and entered into
the next round. In Delphi rounds 2 and 3, we also provided
stakeholders with information about how the other stake-
holders had scored the questions in the prior Delphi round
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(the mean and range of the clinical benefit/importance scores)
as well as a brief synopsis of comments and changes we made
to the questions. Following completion of step 5, we elimi-
nated 4 of the 19 research questions, as 3 had failed to achieve
consensus and 1 had achieved consensus but as having me-
dium clinical benefit/importance.12
During Delphi round 1, national stakeholders additionally
commented on the study needs, challenges, and feasibility
issues that had been identified from the local stakeholders’
meeting. Comments on study needs, challenges, and feasi-
bility were collated with the feedback from the local stake-
holder meeting and organized into the PICOS framework. We
did not require consensus on these topics.
Step 6: Prioritization by national stakeholders
of outcomes for the two questions
on medication and delivery management
During Delphi round 3, national stakeholders completed
step 6 of the process by prioritizing the maternal and fetal
outcomes related to the research questions on medication and
delivery management (which corresponded to the original
review’s questions I and II). We focused on these research
questions because they had high potential for clinical benefit,
were the most amenable to the clinical trial design, and had a
long list of outcomes necessitating priority ranking. From a
list of > 20 possible outcomes that had been suggested in steps
1 through 4, each stakeholder ranked their top three outcomes
that would be most important to include in a clinical trial that
assessed medication and delivery management.
Steps 7 and 8: Refinement of 15 questions
and evaluation of process by all participants
Step 7 involved the final refinement of the questions after
Delphi round 3 and the development of a conceptual frame-
work to display the results of the process, which included
high priority questions and outcomes.
In step 8, we developed an online evaluation tool (using
SurveyGizmo) and invited all systematic review authors
(except the three who were involved with this project) and
local and national stakeholders to evaluate the process. We
asked them to comment on whether they had adequate in-
formation to participate effectively, which mode of partici-
pation they would have preferred (i.e., web-based survey,
phone, in-person), whether they believed that we had ac-
complished our objective, whether the representation of the
local and national stakeholder groups was sufficiently com-
prehensive, and whether we needed each of the eight steps in
the process to accomplish our aim.
Results
Identification of 15 research questions
with high clinical importance and benefit
We developed an eight-step process, using a systematic
review on GDM10 as a starting point and incorporating
feedback from multidisciplinary stakeholders to identify 15
high priority research questions on GDM. Table 1 displays the
15 questions and the mean and range of the clinical impor-
tance/benefit scores from the Delphi round where each
achieved consensus. We organized the research questions by
the 2008 review’s questions’ topics. Based on feedback from
the local stakeholders, we added questions to address the
prevention of type 2 diabetes in women with GDM and ad-
herence to recommendations on postpartum screening for
type 2 diabetes.
Regarding medication management of GDM, both local
and national stakeholders agreed that the effectiveness and
safety of oral hypoglycemic agents in pregnancy have not
clearly been established, even though they are commonly
used in clinical practice. Stakeholders rated comparisons of
sulfonylureas with insulin as having the highest clinical
benefit/importance, with a mean score of 8.2 on a scale of 1
(lowest) to 9 (highest). National stakeholders were also in-
terested in examining the long-term effects of treatment on
offspring, particularly metformin as an insulin sensitizer
(Table 1).
National stakeholders reached consensus that identifying
risk factors for type 2 diabetes in women with GDM was of
high clinical importance and benefit, particularly to guide
future preventive interventions. Research that addresses
maternal health behaviors (e.g., breastfeeding, physical ac-
tivity, diet) received the second highest clinical benefit/
importance score out of the 15 questions (mean score 8.1). In
Delphi round 1, national stakeholders also highlighted that
future research on genetics, including the gene-environment
interaction, would have high potential benefit. Although the
local stakeholders with input into the patient perspective had
suggested examining psychosocial factors (e.g., anxiety and
postpartum depression) as risk factors for the development of
type 2 diabetes, national stakeholders rated these questions
with low clinical importance/benefit; thus, they were ex-
cluded from the final list (Table 1).
The two research questions addressing delivery manage-
ment for women with GDM achieved consensus as having
high clinical benefit and importance because of a dearth of
evidence in this clinically important area. Both local and na-
tional stakeholders emphasized the importance of including
patient-oriented outcomes for these questions, such as satis-
faction with delivery care.
Finally, stakeholders generally agreed that patient and
provider adherence to postpartum testing recommendations
has higher clinical importance than assessment of the per-
formance characteristics of the various screening tests.
Prioritization of outcomes for future studies
of medication or delivery management
Table 2 lists the highest priority maternal and offspring
outcomes, defined as appearing in the top 3 list of two or more
of the nine national stakeholders. These outcomes were
identified as being high priority for future studies assessing
the impact of medication or delivery management on GDM.
When assessing the impact of medication management, four
of nine stakeholders ranked the long-term offspring outcome
of chronic diseases (e.g., obesity, type 2 diabetes) as one of
their top 3, making it the highest rated outcome. The next
most highly rated outcomes were the short-term maternal
outcomes of hypertensive disorders of pregnancy (e.g., ges-
tational hypertension, preeclampsia) and medication adher-
ence and the neonatal outcomes of large for gestational age
and macrosomia.
When assessing the impact of delivery management, the
highest priority outcome, for which six of nine stakeholders
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ranked as one of the top 3 outcomes, was cesarean de-
livery, including primary and repeat cesarean delivery as
well as the indications for cesarean delivery (e.g., sus-
pected macrosomia, birth weight). Cesarean delivery was
followed by the neonatal outcomes of birth trauma, highly
ranked by four of nine stakeholders, and neonatal inten-
sive care unit admission, highly ranked by three of nine
stakeholders.
Conceptual framework
Figure 1 displays the conceptual framework to illustrate the
results of the process. The framework displays the highly
clinically important research questions addressing the man-
agement of GDM during pregnancy, delivery, and the post-
partum period, as well as the high priority outcomes.
Feasibility and study design challenges
At each step of the process, report authors, local stake-
holders, and national stakeholders commented on the feasi-
bility of addressing the research gaps, study design needs,
and potential challenges. Where possible, we organized and
presented these comments in the PICOS framework. Overall,
stakeholders concurred that it would be feasible to design
studies to address the research gaps in GDM. In terms of
selecting a population, stakeholders noted the need for racial
diversity and applying standard methods for the diagnosis of
GDM. In terms of interventions, stakeholders noted a need for
pharmacologic and pharmacokinetic studies, including the
development of animal models, to examine the effects of oral
medications on the fetus and neonate. When considering
comparators of interest, stakeholders noted challenges with
Table 1. Final 15 Research Questions on Gestational Diabetes Mellitus
with High Clinical Importance/Benefit
Clinical importance/
benefit scorea
Research questions Mean Range
Medication management of GDM
What are the comparative effectiveness and safety of
Sulfonylureas compared with any insulin 8.2 7–9
Metformin compared with any insulin 7.9 6–9
Various insulin regimens in terms of type/duration, dosing, and frequency of administration 7.3 6–9
Other drug classes (e.g., thiazolidinediones, DPP-4 inhibitors) compared with any insulin or
oral agent
6.9 4–9
Delivery management for women with GDM
What are the comparative effectiveness and safety of
Elective labor induction at 40 weeks compared with expectant management 7.8 6–9
Elective cesarean delivery at 40 weeks compared with expectant management 7.3 4–9
Risk factors for type 2 diabetes
What is the evidence that each of the following factors is associated with the development of glucose intolerance
and diabetes following a pregnancy with GDM?
Maternal health behaviors (e.g., breastfeeding, physical activity, diet) 8.1 7–9
Comorbid conditions (e.g., advanced age, obesity, hypertension) 7.4 6–9
Maternal metabolic measures (e.g., fasting insulin) 7.3 6–8
Family history, gene mutations, gene-environment interactions 7.4 3–9
Prevention of type 2 diabetes
What is the comparative effectiveness of the following in preventing type 2 diabetes, glucose intolerance, and obesity?
Lifestyle interventions (e.g., exercise, diet) 7.7 6–9
Educational and behavioral interventions (patient education on diabetes risk, lactation support) 7.3 2–9
Screening for type 2 diabetes
What are the performance characteristics of the following tests and what is the optimal screening interval?
Single fasting blood glucose compared with 2-hour oral glucose tolerance test 6.7 1–9
HbA1c testing compared with 2-hour oral glucose tolerance test 7.9 6–9
What is the comparative effectiveness of strategies to improve patient and clinician adherence
with postpartum screening recommendations?
7.8 5–9
The 4 research questions excluded and reason in parentheses:
1. What is the evidence that the interconception interval is associated with the risk of developing type 2 diabetes or glucose intolerance/
impaired fasting glucose following GDM? (Consensus of medium level of importance)
2. What is the evidence that maternal psychosocial factors (e.g., mood disorders, substance use disorders, eating disorders, stress) are
associated with the risk of developing type 2 diabetes or glucose intolerance/impaired fasting glucose following GDM? (No consensus
achieved)
3. What is the evidence that contraceptive method (e.g., progestin-only) is associated with the risk of developing type 2 diabetes or glucose
intolerance/impaired fasting glucose following GDM? (No consensus achieved)
4. What is the comparative effectiveness of health information technology interventions to track postpartum screening for the development
of type 2 diabetes and glucose intolerance/impaired fasting glucose in women with a history of GDM? (No consensus achieved)
aScore was on a scale of 1–9 where 1 = lowest clinical importance or benefit and 9 = highest clinical benefit or importance. Mean and range of
scores are provided for the Delphi round in which the listed question achieved consensus.
DPP-4, Dipeptidyl-peptidase-4; HbA1c, hemoglobin A1c.
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Table 2. Highest Priority Outcomes to Assess Impact of Medication or Labor Management






Medication management of GDM
Short-term outcomes
Hypertensive disorders of pregnancy (e.g., gestational hypertension, preeclampsia) 3
Medication adherence 3
Large for gestational age and macrosomia 3
Gestational weight gain 2
Neonatal hypoglycemia 2
Neonatal intensive care unit admission 2
Long-term outcomes
Chronic disease incidence in offspring (e.g., obesity, type 2 diabetes) 4
Postpartum incident type 2 diabetes mellitus or glucose intolerance/impaired fasting glucose 2
Delivery management for women with GDM
Short-term outcomes
Cesarean delivery (including primary cesarean and repeat cesarean) and indication for cesarean deliverya 6
Birth trauma (e.g., bone fractures, brachial plexus palsy) 4
Neonatal intensive care unit admission 3
Patient-reported outcomes (e.g., patient preference, quality of life) 2
Complications of cesarean delivery (e.g., wound infection, wound dehiscence) 2
Vaginal delivery (spontaneous, operative) 2
Hypoxia/anoxia 2
Respiratory distress syndrome 2
Defined as ‡ two of nine national stakeholders ranked it among top 3 outcomes to measure in future studies.
The outcomes that were not ranked in the top 3 by ‡ two of nine stakeholders were:
Medication management of GDM—glycemic control, patient-reported outcomes (e.g., patient treatment preference, quality of life),
cesarean delivery and indication, complications of cesarean delivery (e.g., wound infection), other obstetric complications (e.g., birth trauma,
shoulder dystocia, perineal lacerations, postpartum hemorrhage), neonatal complications (e.g., hypoxia/anoxia, hypoglycemia, respiratory
distress syndrome, hyperbilirubinemia), peripartum mortality, birth weight, postpartum weight retention, longer-term infant, and child
growth.
Delivery management of GDM—resource utilization (e.g., cost of care, length of stay), peripartum mortality, birth weight (and large or
small for gestational age, macrosomia), other obstetric complications (e.g., perineal lacerations, postpartum hemorrhage, pulmonary
embolism), other neonatal complications (e.g., neonatal hypoglycemia, perinatal mortality).
FIG. 1. Conceptual framework displaying high priority research needs (in italics) addressing pregnancy, delivery, and
postpartum management of gestational diabetes mellitus (GDM), with examples of high priority outcomes. NICU, neonatal
intensive care unit.
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designing an RCT to address the comparative effectiveness of
delivery management strategies. They discussed the poten-
tial risk of high crossover between arms because of patient
and provider preference for delivery mode (Table 1). To ad-
dress medication comparisons, they suggested a need for
large, well-designed prospective observational studies in
large medical centers (or collaborating centers), with strati-
fication by GDM therapies (e.g., diet vs. insulin). Such studies
could be completed in a shorter period of time than a trial,
thus mitigating the impact of changing practice patterns, and
could lead to long-term prospective cohorts to examine both
high priority maternal and offspring outcomes (Table 2).
Finally, stakeholders highlighted the need for future studies
to apply standard outcome definitions, such as for hypo-
glycemia, and to aim for complete, consistent outcome as-
certainment to improve the ability to make comparisons
between studies.
Evaluation of the eight-step process
All 20 contributors, including 5 authors of the original
systematic review, 6 local stakeholders and 9 national stake-
holders, completed evaluations on the eight-step process and
their involvement. Saldanha et al.13 included a complete de-
scription of the evaluation results. After review of the final list
of 15 research questions and a summary of the eight-step
process, evaluators responded that they had ‘‘adequate in-
formation to effectively participate’’ in the process and that
our research team ‘‘had accomplished the objective of iden-
tifying important research questions for GDM.’’
Discussion
Using a systematic review on GDM as a starting point, we
developed an eight-step process, which included stakeholder
feedback to identify and prioritize 15 clinically important re-
search questions in GDM. The research questions focused on
medication management of GDM, delivery management for
patients with GDM, identification of risk factors for type 2
diabetes in women with prior GDM, prevention of type 2
diabetes and other chronic diseases in women with prior
GDM, and postpartum screening for type 2 diabetes. Stake-
holders expressed high levels of interest in examining medi-
cation comparisons, particularly sulfonylureas vs. insulin,
and the influence of maternal lifestyle factors in the subse-
quent development of type 2 diabetes. In addition, stake-
holders ranked long-term offspring chronic disease, cesarean
delivery, and birth trauma as high priority outcomes to in-
clude when designing clinical trials and proposed key study
design elements to increase research yield.
To our knowledge, ours is the first study to develop a
method for identification of high priority research questions
in the field of GDM. Prior research on identification of re-
search needs in other disease areas has focused on the prior-
itization20 or the presentation of research needs.21 Recently,
members of our team (K.A.R., I.J.S.) developed other frame-
works to identify research needs using evidence-based clinical
practice guidelines22 and systematic reviews11 but did not
involve stakeholders. Our process for identifying high prior-
ity research questions has implications for a broader appli-
cation beyond the field of GDM by using systematic reviews
to identify future research needs and formulate researchable
questions with stakeholder input. We invited committed,
multidisciplinary stakeholders to comment on and refine the
questions to ensure a balanced and broad perspective on re-
search needs in GDM. Stakeholders were able to efficiently
use the Delphi method to share comments and classify the
clinical benefit of the questions to come to consensus.
We believe that these 15 high priority research questions
will be useful to GDM researchers, funders, and policy-
makers. Based on the low and insufficient quality of evidence
in the published systematic review,10 substantial gaps in the
evidence exist. GDM continues to be a very active area of
research, with several major treatment trials published,8,23,24
as well as ongoing innovative trials on diabetes prevention in
women with recent GDM.25 In addition, policymakers are
particularly interested in boosting funding in GDM. In 2010,
the U.S. House of Representatives passed the Gestational
Diabetes Act (GEDI Act) to increase funding to the Centers
for Disease Control and Prevention (CDC) for research in
GDM.26 The 15 questions we identified can provide a tool
for researchers and funders planning high impact grants to
target areas with existing gaps and where results are likely to
be quickly translated into clinical practice. Of particular in-
terest, with high potential for clinical benefit, are trials
comparing medications for treatment of GDM, with attention
to outcomes that are not traditionally measured, such as
medication adherence, comorbid hypertensive disorders in
pregnancy, and longer-term offspring outcomes. Studies
examining the role of maternal lifestyle factors in the devel-
opment of type 2 diabetes will also have high clinical impact,
if funded.
Several limitations to our study deserve mention. First, we
invited nonresearch-oriented clinicians who work closely
with patients, but their feedback may have been limited by the
complexity of the research in the project and amount of in-
formation presented from the 2008 review. Although we did
not include patients in the process we reported here, devel-
oping methods that involve patients in identifying and pri-
oritizing research gaps is extremely important. The local
stakeholders’ group proposed questions about psychosocial
factors, which would have provided insight from the patients’
perspectives. Unfortunately, these questions were not
deemed of high clinical importance in subsequent Delphi
rounds, highlighting the necessity for a systematic and effec-
tive way to elicit and incorporate patients’ perspectives
without risking their input being superseded by other stake-
holders. Second, the eight steps were resource intense and
may not be feasible or practical to conduct following all sys-
tematic reviews. Third, there may be additional useful steps to
refine these research needs and questions, as well as to iden-
tify possible study designs for future research. For example,
additional steps may include an update of the literature
search in the 2008 systematic review, a search for ongoing
studies, or more systematic discussion about appropriate
study designs and the feasibility of addressing the 15 ques-
tions with involved stakeholders. Fourth, because we used the
2008 systematic review as a starting point, our project had a
similar scope and, thus, did not assess research needs related
to screening or diagnostic criteria for GDM, which are im-
portant, actively debated topics and will be addressed in an
upcoming AHRQ evidence report and NIH consensus panel
in the fall of 2012.27 We believe our findings to be useful and
significant, however, as the topics addressed in the 2008 re-
view were suggested by the ACOG because of their high
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clinical relevance, and our process engaged multiple stake-
holders beyond the results of the 2008 review.
Conclusions
Using a comprehensive systematic review on GDM as a
starting point, we developed an eight-step process and iden-
tified 15 research questions on GDM management considered
of high clinical importance by a multidisciplinary group of
stakeholders. We prioritized outcomes to be examined in fu-
ture studies on medication and delivery management. We
anticipate that our process could be used as is or modified as
necessary as a model for taking the results of other systematic
reviews to the next stage, toward identification of research-
able questions in areas of highest clinical importance. These 15
questions can be used by researchers and funders to target
areas of highest need for future research in GDM to make a
significant clinical impact in this rapidly growing field.
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